Performance of newer myeloma staging systems in a contemporary, large patient cohort
Blood Cancer J
.
2024 Jun 11;14(1):95.
doi: 10.1038/s41408-024-01076-w.
Authors
Ghulam Rehman Mohyuddin
1
,
Samuel M Rubinstein
2
,
Shaji Kumar
3
,
S Vincent Rajkumar
3
,
Rafael Fonseca
4
,
Nadine H Abdallah
3
,
Gregory S Calip
5
,
Xiaoyan Wang
6
,
Christina M Parrinello
7
,
Douglas Sborov
8
Affiliations
1
Huntsman Cancer Institute, University of Utah, Salt lake, UT, USA. g.mohyuddin@hci.utah.edu.
2
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
3
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
4
Division of Hematology, Mayo Clinic, Phoenix, AZ, USA.
5
Titus Family Department of Clinical Pharmacy, University of Southern California, Los Angeles, CA, USA.
6
Flatiron Health, New York, NY, USA.
7
Pine Mountain Consulting, Larkspur, CA, USA.
8
Huntsman Cancer Institute, University of Utah, Salt lake, UT, USA.
PMID:
38862493
PMCID:
PMC11166956
DOI:
10.1038/s41408-024-01076-w
No abstract available
Publication types
Letter
MeSH terms
Adult
Aged
Aged, 80 and over
Cohort Studies
Female
Humans
Male
Middle Aged
Multiple Myeloma* / diagnosis
Multiple Myeloma* / pathology
Multiple Myeloma* / therapy
Neoplasm Staging*
Grants and funding
P50 CA186781/CA/NCI NIH HHS/United States